A phenotyping-cocktail study found age-related differences in midazolam pharmacokinetics, including in older adults with kidney disease.
What the source reports
The investigators compared healthy younger adults, healthy older adults, and older adults with chronic kidney disease using low-dose probe drugs. Midazolam exposure increased and its half-life was prolonged in older groups. The study also examined other CYP3A substrates and transporter probes.
Limits of the evidence
Microdose findings do not automatically scale to every therapeutic regimen. Group differences in body characteristics and other factors require attention, and some transporter findings were inconclusive. This study did not directly measure benzodiazepine-related functional performance.
Implications for forensic review
Age and renal disease may matter even when a drug is discussed primarily in terms of hepatic metabolism. For case analysis, separate changes in exposure from observed effects and examine co-medications. A population pharmacokinetic difference cannot substitute for a patient’s actual administration and recovery record.
Source and related reading
Source reviewed: Quantification of CYP3A and Drug Transporters Activity in Healthy Young Healthy Elderly and Chronic (PMC8486002). This article summarizes the supplied paper; forensic applications above are interpretive analysis.
Related reading: Lisdexamfetamine Did Not Meaningfully Change Midazolam Exposure in a Healthy-Volunteer Study; Unchanged Midazolam Exposure Does Not Establish Absence of Every Lemborexant Interaction.
Leave a Reply